ARMGO Pharma gets $1 million to aid ARM210 preclinical work for DMD treatment ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work to get an Investigational New Drug software with the U.S Can you buy prescription drugs online legally? . Food and Medication Administration for ARM210, a novel, available orally, small-molecule Rycal drug which has potential as cure for Duchenne muscular dystrophy . The financing award to ARMGO Pharma originates from MDA Venture Philanthropy , part of MDA's translational research program. Related StoriesFlorida Institute finalizes financing contract with Genetic NetworksTesting amniotic fluid could information doctors to make delivery planning decisions for preterm birthsDisclosing genetic risk for CHD outcomes in lower low-density lipoprotein cholesterol DMD is one of nine types of muscular dystrophy, a combined band of genetic, degenerative diseases primarily affecting voluntary muscles.
Given that AR-V7 has been associated with level of resistance to hormone therapy but not chemotherapy, the authors speculated that AR-V7-positive sufferers should probably be offered chemotherapy instead of hormone therapy as preliminary treatment for mCRPC. Sufferers who are AR-V7-unfavorable, however, can safely choose either regimen. Related StoriesMultigene check performed on tumor can recognize breast cancer individuals who can safely prevent chemotherapyChemotherapy treatment can contribute to long-term neurocognitive deficits in pediatric human brain tumor survivorsGenetic check identifies breast cancer sufferers that may avoid chemotherapy and remain relapse-free of charge following five years of hormone therapyThis may be the first clinical study to explore the association between AR-V7 status and outcomes after treatment with taxane chemotherapy in individuals with mCRPC.